| Recombinant Human Parvovirus B19 Virus-Like Particle Vaccine |
| |
|
|
Recombinant Parvovirus B19
virus like particles
manufactured by Meridian
|
Meridian Life Science, Inc. manufactured, and subsequently licensed, a recombinant Parvovirus B19 (HPVB19) vaccine under a contract from the National Heart, Lung and Blood Institute of the National Institutes of Health. The vaccine was manufactured according to cGMP and has been used in Phase I/II safety/efficacy trials. The vaccine consists of two viral proteins (VP1 and VP2) in separate Baculovirus vectors that are co-infected at the correct multiplicity of infections (MOI’s) into Sf9 cells and that, upon expression, self assemble into immunogenic virus-like particles. Meridian Life Science has a validated cGMP vialing line for this product of up to 2,500 vials. |
Paravovirus B19 from
patient sample by TEM
|
| |
 |
| Background of Human Parvovirus B19: |
|
- Parvoviruses are small DNA viruses that infect rapidly dividing cells and cause a diversity of diseases in animal species
- Parvovirus B19 is the only Parvoviridae species to cause disease in man
- Global and common infection in humans
|
- HPVB19 Infection in the Healthy Host:
|
- Fifth Disease: in normal individuals, Parvovirus B19 causes a rash illness in children (Fifth disease) and an arthralgia syndrome in adults
- Human virulence varies by age, immunologic, and hematologic status
- Typical prevalence of IgG antibodies against HPVB19:
|
| |
|
 |
|
| |
|
- HPVB19 Infection in Susceptible Populations:
|
- Transient Aplastic Crisis: In patients with underlying Hemolysis, HPVB19 causes temporary cessation of red cell production and severe anemia; can be fatal
- Sickle Cell Anemia
- Other genetic hemolytic anemias
- Immunosuppressed individuals, HPVB19 persists and causes severe anemia and pure red cell aplasia
- HPVB19 infection during pregnancy can result in transmission to the fetus, hydrops fetalis, and fetal loss
|
| |